Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAIC 2026 | Clinical application of plasma p-tau217 in cognitively unimpaired individuals

Rachel Buckley, PhD, Mass General Brigham, Boston, MA, discusses the potential clinical applications of plasma p-tau217 in cognitively unimpaired individuals. Dr Buckley highlights that successful secondary prevention trials are needed before these tests can be widely used. This interview took place at the 2026 Alzheimer’s Association International Conference (AAIC) in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Yeah, I think the really exciting thing about this work is it’s a first step towards trying to understand what P-tau217 can tell us in cognitively unimpaired individuals. One of the issues right now is that we do not have clinical recommendations to say that people who are cognitively unimpaired should get a plasma test. So right now there’s no recommendations for that. But what this study does is it puts us, you know, gets us that first step towards thinking about the possibility of being able to employ this clinically...

Yeah, I think the really exciting thing about this work is it’s a first step towards trying to understand what P-tau217 can tell us in cognitively unimpaired individuals. One of the issues right now is that we do not have clinical recommendations to say that people who are cognitively unimpaired should get a plasma test. So right now there’s no recommendations for that. But what this study does is it puts us, you know, gets us that first step towards thinking about the possibility of being able to employ this clinically. Now, when would we look to do that? When would we be able to scale up and use plasma P-tau217 tests in cognitively unimpaired individuals? Well, that will be once we start to see successful secondary prevention trials coming out. And I would like to say I wish I had touched wood somewhere, but I do feel optimistic that in the next 12 to 18 months, we will hopefully see successful secondary prevention therapies coming out, in which case we will all of a sudden need to have scalable blood tests that can be used to detect and help prognosticate somebody’s likelihood of clinical or cognitive impairment over time. And that will not only give the patient information on the likelihood of progressing, but also it will allow the clinician to be able to funnel people through into the therapeutic pipeline so that they can have that prevention therapy straight away. So that’s sort of where we’re positioning ourselves. We’re still early days. We cannot start doing that yet, but we’re hoping that that will change very soon.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...